Feedback / Questions
NKT5097 - NiKang Therap
https://www.businesswire.com/news/home/20251211303516/en/NiKang-Therapeutics-Presents-Discovery-of-NKT5097-a-First-in-Class-Highly-Potent-and-Selective-Orally-Bioavailable-CDK24-Dual-Degrader-for-Cancer-Therapy-at-SABCS-2025
Dec 11, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next